Provider of microfluidics-based technology for the encapsulation of microbial and mammalian cells. The company has developed a microfluidics instrument called Xdrop that encapsulates the target living cells, DNA fragments, or organelles together with the assay chemistry is highly stable double-emulsion droplets. It has applications for cell reaction screening and verification of gene edits. The company was founded in 2013 and headquartered in Birkerod, Denmark. It has raised $12.8M in series a funding, with backing from EIC Fund, Europa, Fjord Capital Partners, Jersey Finance. The company operates in the Life Sciences - Genomics, Life Sciences - Life Sciences Platforms and Tools space.
← All startups
Samplix ApS
Series AProvider of microfluidics-based technology for the encapsulation of microbial and mammalian cells. The company has developed a microfluidics instrument called Xdrop that encapsulates the target living cells, DNA fragments, or organelles together with the assay chemistry is highly stable double-emulsion droplets. It has applications for cell reaction screening and verification of gene edits. The company was founded…
About
Business model
Genomics > Enabling Technologies > Instrument Systems > Nucleic Acid Analysis > Amplification > Whole Genome Amplification,
Life Sciences Platforms and Tools > Instruments > Microfluidics
Institutional investors
EIC FundEuropaFjord Capital PartnersJersey FinanceChristopher John Nicholas BradenGeorg Von Werz
Latest coverage
📰 Browse funding news — rounds, valuations, and market moves for founders.
Investor directory
🗂️ Full list of active funds — filter by stage, check size, and geography.